Drugs.com - FDA MedWatch Alerts

Drug Safety Communication: Ocaliva (obeticholic acid) - Serious Liver Injury Being Observed in Patients without Cirrhosis

Audience: Gastroenterology, Hepatology, Patient, Health Care Professional, Pharmacy ISSUE: The FDA identified cases of serious liver injury among patients being treated for primary biliary cholangitis (PBC) with Ocaliva (obeticholic acid) who did...

Feb 9, 2025 - 21:44
 0
Drug Safety Communication: Ocaliva (obeticholic acid) - Serious Liver Injury Being Observed in Patients without Cirrhosis
Audience: Gastroenterology, Hepatology, Patient, Health Care Professional, Pharmacy ISSUE: The FDA identified cases of serious liver injury among patients being treated for primary biliary cholangitis (PBC) with Ocaliva (obeticholic acid) who did...
Read More

Tags:

Previous Article

FDA Adds Boxed Warning to Veozah (fezolinetant) to Highlight the Known Risk of R...

Next Article

Buy-herbal.com Issues Voluntary Nationwide Recall of Nhan Sam Tuyet Lien Truy Ph...

Related Posts

Endo USA, Inc. Issues Recall of One Lot of Clonazepam Orally Disintegrating Tablets Due to Mislabeling: Incorrect Strength on Product Carton

Endo USA, Inc. Issues Recall of One Lot of Clonazepam O...

Feb 9, 2025  0

Do Not Purchase or Use Skin-Cap Aerosol Spray Products Because They May Be Harmful to Your Health

Do Not Purchase or Use Skin-Cap Aerosol Spray Products ...

Feb 9, 2025  0

Provepharm Inc. Issues Recall of One Lot of Phenylephrine Hydrochloride Injection, USP, 10 mg/ mL (Pharmacy Bulk Package) Due to Presence of Particulate Matter

Provepharm Inc. Issues Recall of One Lot of Phenylephri...

Feb 9, 2025  0